Pfizer and generics – leveraging its established business
This article was originally published in Scrip
Executive Summary
Pfizer is doing everything it can to prepare for a sales decline when its best-selling product Lipitor (atorvastatin) goes off patent. First it was the $68 billion acquisition of Wyeth, and now it is turning to generics through the recent licensing deal with Aurobindo Pharma.